A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir Disoproxil Fumarate (MVC+TDF), or Tenofovir Disoproxil Fumarate + Emtricitabine (TDF+FTC) For Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Transmission in At-Risk Men Who Have Sex With Men and in At-Risk Women.

Trial Profile

A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir Disoproxil Fumarate (MVC+TDF), or Tenofovir Disoproxil Fumarate + Emtricitabine (TDF+FTC) For Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Transmission in At-Risk Men Who Have Sex With Men and in At-Risk Women.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Emtricitabine; Maraviroc; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Adverse reactions
  • Acronyms NEXT-PrEP
  • Most Recent Events

    • 10 Oct 2013 New source identified and integrated (University of Washington Health Sciences; 42683).
    • 30 Aug 2013 Planned End Date changed from 1 Jan 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 12 Feb 2013 Planned number of patients changed from 400 to 600 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top